• 1
    Têtu B, Srigley JR, Boivin J-C et al. Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma: A histopathologic and immunohistochemical study. Am J Surg Pathol 1991; 15: 11120.
  • 2
    Armas OA, Aprikian AG, Melamed J et al. Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol 1994; 18: 97991.
  • 3
    Vaillancourt L, Têtu B, Fradet Y et al. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma: A randomized study. Am J Surg Pathol 1996; 20: 8693.
  • 4
    Bullock MJ, Srigley JR, Klotz LH, Goldenberg SL. Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: A detailed analysis of radical prostatectomy specimens from a randomized trial. Am J Surg Pathol 2002; 26: 140013.
  • 5
    Bostwick DG, Meiers I. Diagnosis of prostatic carcinoma after therapy: Review 2007. Arch Pathol Lab Med 2007; 131: 36071.
  • 6
    Humphrey PA. Diagnosis of adenocarcinoma in prostate needle biopsy tissue. J Clin Pathol 2007; 60: 3542.
  • 7
    Epstein JI, Algaba F, Allsbrook WC Jr et al. Acinar adenocarcinoma. Tumours of the prostate. In: EbleJN, SauterG, EpsteinJI, SesterhennIA, eds. World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press, 2004; 15992.
  • 8
    Parwani AV, Marlow C, Demarzo AM et al. Immunohistochemical staining of precursor forms of prostate-specific antigen (proPSA) in metastatic prostate cancer. Am J Surg Pathol 2006; 30: 12316.
  • 9
    Lam JS, Yamashiro J, Shintaku IP et al. Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin Cancer Res 2005; 11: 25916.
  • 10
    Gelmann EP, Bowen C, Bubendorf L. Expression of NKX3.1 in normal and malignant tissues. Prostate 2003; 55: 11117.
  • 11
    Hughes C, Murphy A, Martin C, Sheils O, O’Leary J. Molecular pathology of prostate cancer. J Clin Pathol 2005; 58: 67384.
  • 12
    Challita-Eid PM, Morrison K, Etessami S et al. Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo. Cancer Res 2007; 67: 5798805.
  • 13
    Alanen KA, Kuopio T, Koskinen PJ, Nevalainen TJ. Immunohistochemical labelling for prostate specific antigen in non-prostatic tissues. Pathol Res Pract 1996; 192: 2337.
  • 14
    Chang SS. Overview of prostate-specific membrane antigen. Rev Urol 2004; 6: S1318.
  • 15
    Xu J, Stolk JA, Zhang X et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res 2000; 60: 167782.
  • 16
    Jiang Z, Woda BA, Rock KL et al. P504S: A new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol 2001; 25: 1397404.
  • 17
    Luo J, Zha S, Gage WR et al. a-Methylacyl-CoA racemase: A new molecular marker for prostate cancer. Cancer Res 2002; 62: 222026.
  • 18
    Beach R, Gown AM, De Peralta-Venturina MN et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol 2002; 26: 158896.
  • 19
    Zhou M, Jiang Z, Epstein JI. Expression and diagnostic utility of alpha-methylacyl-CoA-racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer. Am J Surg Pathol 2003; 27: 7728.
  • 20
    Suzue K, Montag AG, Tretiakova M, Yang XJ, Sahoo S. Altered expression of a-methylacyl-coenzyme A racemase in prostatic adenocarcinoma following hormone therapy. Am J Clin Pathol 2005; 123: 55361.
  • 21
    Tang X, Serizawa A, Tokunaga M et al. Variation of a-methylacyl-CoA racemase expression in prostate adenocarcinoma cases receiving hormonal therapy. Hum Pathol 2006; 37: 118692.
  • 22
    Xu J, Kalos M, Stolk JA et al. Identification and characterization of prostein, a novel prostate-specific protein. Cancer Res 2001; 61: 15638.
  • 23
    Kalos M, Askaa J, Hylander BL et al. Prostein expression is highly restricted to normal and malignant prostate tissues. Prostate 2004; 60: 24656.
  • 24
    Sheridan T, Herawi M, Epstein JI, Illei PB. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate. Am J Surg Pathol 2007; 31: 13515.
  • 25
    Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases. Cancer 1998; 82: 225661.
  • 26
    Ross JS, Sheehan CE, Fisher HAG et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003; 9: 635762.
  • 27
    Chuang A-Y, DeMarzo AM, Veltri RW et al. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol 2007; 31: 124655.
  • 28
    Perner S, Hofer MD, Kim R et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 2007; 38: 696701.
  • 29
    Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005; 29: 122842.
  • 30
    Goldstein NS, Underhill J, Roszka J, Neill JS. Cytokeratin 34βE-12 immunoreactivity in benign prostatic acini: Quantitation, pattern assessment, and electron microscopic study. Am J Clin Pathol 1999; 112: 6974.
  • 31
    Martens MB, Keller JH. Routine immunohistochemical staining for high-molecular weight cytokeratin 34-β and a-methylacyl CoA racemase (P504S) in postirradiation prostate biopsies. Mod Pathol 2006; 19: 28790.
  • 32
    Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate of high Gleason scores. Am J Clin Pathol 2002; 117: 4717.
  • 33
    Wright GL Jr, Grob BM, Haley C et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996; 48: 32634.
  • 34
    Chang SS, Reuter VE, Heston WDW, Hutchinson B, Grauer LS, Gaudin PB. Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues. Cancer 2000; 88: 40715.
  • 35
    Pendleton J, Pisters LL, Nakamura K, Anai S, Rosser CJ. Neoadjuvant therapy before radical prostatectomy: Where have we been? Where are we going? Urol Oncol 2007; 25: 1118.
  • 36
    Powell IJ, Tangen CM, Miller GJ et al. Neoadjuvant therapy before radical prostatectomy for clinical T3/4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109. J Urol 2002; 168: 201619.